Impact of disease location on fecal calprotectin levels in Crohn’s disease

References

• GD’Haens, MFerrante, SVermeire, FBaert, MNoman, LMoortgat, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–24.
   PubMed Web of Science ®Google Scholar
• LPeyrin-Biroulet, WReinisch, JFColombel, GJMantzaris, AKornbluth, RDiamond, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63:88–95.
   PubMed Web of Science ®Google Scholar
• AMSchoepfer, CBeglinger, AStraumann, MTrummler, SRVavricka, LEBruegger, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162–9.
   PubMed Web of Science ®Google Scholar
• JLanghorst, SElsenbruch, JKoelzer, ARueffer, AMichalsen, GJDobos. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162–9.
   PubMed Web of Science ®Google Scholar
• SVermeire, GVan Assche, PRutgeerts. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426–31.
   PubMed Web of Science ®Google Scholar
• JTibble, KTeahon, BThjodleifsson, ARoseth, GSigthorsson, SBridger, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.
   PubMed Web of Science ®Google Scholar
• MDaperno, GD’Haens, GVan Assche, FBaert, PBulois, VMaunoury, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• JFRey, RLambert, EQACommittee. ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. Endoscopy 2001;33:901–3.
   PubMed Web of Science ®Google Scholar
• MDJensen, JKjeldsen, TNathan. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol 2011;46:694–700.
   PubMed Web of Science ®Google Scholar
• JJones, EVLoftusJr, RPanaccione, LSChen, SPeterson, JMcConnell, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008;6:1218–24.
   PubMed Web of Science ®Google Scholar
• CGaf Björkesten, UNieminen, UTurunen, PArkkila, TSipponen, MFarkkila. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol 2012;47:528–37.
   PubMed Web of Science ®Google Scholar
• TSipponen, PKarkkainen, ESavilahti, KLKolho, HNuutinen, UTurunen, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008;28:1221–9.
   PubMed Web of Science ®Google Scholar
• CAParisinos, VEMcIntyre, THeron, DSubedi, IDArnott, CMowat, et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn’s disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010;16:1219–26.
   PubMed Web of Science ®Google Scholar
• TSipponen, JHaapamaki, ESavilahti, HAlfthan, EHamalainen, HRautiainen, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012;47:778–84.
   PubMed Web of Science ®Google Scholar
• JATibble, GSigthorsson, SBridger, MKFagerhol, IBjarnason. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• KPapamichael, PKaratzas, GJMantzaris. Faecal calprotectin but not C-reactive protein (CRP) or Crohn’s Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn’s disease. J Crohns Colitis 2013;7:e700–1.
   PubMedGoogle Scholar
• TSipponen, CGBjorkesten, MFarkkila, HNuutinen, ESavilahti, KLKolho. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol 2010;45:325–31.
   PubMed Web of Science ®Google Scholar
• TLobaton, ALopez-Garcia, FRodriguez-Moranta, ARuiz, LRodriguez, JGuardiola. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013;7:e641–51.
   PubMedGoogle Scholar
• TSipponen, ESavilahti, KLKolho, HNuutinen, UTurunen, MFarkkila. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.
   PubMed Web of Science ®Google Scholar
• ELouis, JYMary, GVernier-Massouille, JCGrimaud, YBouhnik, DLaharie, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.e5; quiz e31.
   PubMed Web of Science ®Google Scholar
• SJWhitehead, JFrench, MJBrookes, CFord, RGama. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53–61.
   PubMed Web of Science ®Google Scholar
• DLabaere, ASmismans, AVan Olmen, PChristiaens, GD’Haens, VMoons, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014;2:30–7.
   PubMed Web of Science ®Google Scholar
• ALasson, POStotzer, LOhman, SIsaksson, MSapnara, HStrid. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26–32.
   PubMed Web of Science ®Google Scholar
• MDe Vos, EJLouis, JJahnsen, JGVandervoort, MNoman, ODewit, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111–17.
   PubMed Web of Science ®Google Scholar